VivoSeq
Infectious Disease

Bacterial Infection

1

Pipeline Programs↗

5

Active Trials↗

8

Companies Involved↗

Bacterial Infection is an early-stage landscape with 1 program across 8 companies. The most active players are Merck & Co., GSK, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

91/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalJohnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

0 programs

PreclinicalChia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

0 programs

PreclinicalJ

Jiangsu Hengrui Pharmaceutical Co., Ltd.

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved1

Iohexol

GE Healthcare

Analysis

Trial Status

18

clinical trials

Completed10 · 56%
Recruiting3 · 17%
Not yet recruiting2 · 11%
Unknown status2 · 11%
Terminated1 · 6%

Clinical Trials

Trial Activity

18 trials

A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection
Recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logoChia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT06198764·80 enrolled
A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)
Recruiting·Pfizer logoPfizer·Phase 2·NCT06462235·48 enrolled
Optimization of Beta-lactam Dosing in Critically Ill Patients With Suspected or Documented Antimicrobial Resistant Gram-Negative Infections With Cystatin-C (OPTIMIZE-GNI)
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Approved·NCT06709521·200 enrolled
A Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics
Not yet recruiting·GSK logoGSK·Phase 1·NCT07371429·20 enrolled
Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection
Not yet recruiting·SSaptalis Pharmaceuticals LLC·Phase 2·NCT07146217·30 enrolled
A Study of Incidence of Musculoskeletal Disorders in Children Who Have Received Levofloxacin or a Standard Non-Fluoroquinolone Therapy for Acute Bacterial Infection
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logoJohnson & Johnson Pharmaceutical Research & Development, L.L.C.·N/A·NCT00210639·2,233 enrolled
Analysis of Immune Response In Bacterial Infection of Obese Subject
Completed·VVersailles Hospital·N/A·NCT02882568·15 enrolled
A Proof of Concept Study of Inhaled Nitric Oxide for Adults With Pulmonary Non-Tuberculous Mycobacterial Infection
Completed·MMedical University of South Carolina·Phase 2·NCT03748992·10 enrolled
Value for Cord Blood Procalcitonin to Diagnose Early Neonatal Bacterial Infection
Completed·UUniversity Hospital, Montpellier·N/A·NCT02858700·550 enrolled
A Pharmacokinetic Study of LP-001 in Children With a Bacterial Infection
Completed·KKaizen Bioscience Co.·Phase 1·NCT05584683·39 enrolled
Procalcitonin (PCT) as a Diagnostic Marker of Bacterial Infection in the Patients Admitted for Fever and/or Inflammatory Syndrome to the Internal Medicine Department
Completed·—·N/A·NCT02898948·116 enrolled
Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT02452047·50 enrolled
Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)
Completed·Merck & Co. logoMerck & Co.·Phase 2/3·NCT03969901·115 enrolled
A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT02750761·32 enrolled
Exposure to NSAIDs (Non Steroidal Anti-Inflammatory Drugs) and Severity of Community-acquired Bacterial Infections
Completed·NNantes University Hospital·N/A·NCT02794831·335 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)